New Tools in Lifescience Finance

Sep 29, 2013

Corporate partners, philanthropic organizations, royalty finance, “build to suit” …  Who needs a VC anyway?

Whatever happened to the good old Series A?  Can everyone go public now – in forward or reverse?  How do you balance doing good with doing well financially?   Our speakers will tell you!

 REGISTRATION CLOSED @ 10AM on 10/23. LIMITED WALK IN REGISTRATION AVAILABLE $60
Friday, Oct 25, 2013; Hyatt Regency La Jolla
7:00 – 7:30 networking,
7:30 breakfast – 8:00 program starts

more_web

Bob More, Bill and Melinda Gates Foundation


baltera_web

Bob Baltera, former CEO of Amira Pharmaceuticals


Amanda Cashin, PhD Alexandria Real Estate Equities

Amanda Cashin, PhD
Alexandria Real Estate Equities


Our moderator is Bob Baltera, former CEO of Amira Pharmaceuticals and SDVG Board member.  Bob will lead a discussion about lifescience financing outside the traditional VC route.

Bob More of the Bill & Melinda Gates Foundation will discuss his new role and the emerging field of philanthropic investing.  Learn how charitable organizations are seeking to use their financial resources to drive positive outcomes.

Barry Michaels, CFO of our “Cool Company” Organovo, will share his experience utilizing a reverse merger to fund their start-up and working their way to a $500M market cap.

Amanda Cashin, Vice President of Alexandria Real Estate Equities,

Amanda Cashin, PhD, of Alexandria Venture Investments will talk about how the venture capital arm of Alexandria Real Estate Equities, Inc. strategically invests in cutting-edge, disruptive life science companies.
 
Thank you sponsors!
Alexandria_web
 
 
sponsor_logo_wsgrresmed